Главная
Study mode:
on
1
Introduction
2
Prostate cancer statistics
3
Prostate cancer without screening
4
What is PSA
5
Shared Decision Making Process
6
Benefits vs Harms
7
When to Start Screening
8
Diagnosis
9
Risk Groups
10
T Stage
11
Gleason Score
12
Risk Classification
13
Survival
14
Treatment
15
Definitive Therapy
16
UK Protect Trial
17
Conclusion
18
Questions
19
Gleason 4 vs Gleason 3
20
Role of biomarker testing
21
Active surveillance vs watchful waiting
22
Diet and prostate cancer
23
Would you still recommend active surveillance
24
PSA
25
Radiation Therapy
Description:
Explore a comprehensive lecture on prostate cancer diagnosis and management, delivered by Stanford Health Care radiation oncologist Dr. Yushen Qian. Gain insights into risk factors, cancer risk assessment, age-related PSA levels, prostate biopsy procedures, Gleason scoring, and cancer staging. Understand the distinctions between Watchful Waiting and Active Surveillance approaches, and learn when treatment interventions may be necessary. Delve into topics such as prostate cancer statistics, screening benefits and risks, shared decision-making processes, risk classification, survival rates, and various treatment options including definitive therapy and radiation therapy. The lecture also covers the UK Protect Trial findings and addresses questions on biomarker testing, diet's role in prostate cancer, and the continued relevance of active surveillance in prostate cancer management.

Active Surveillance of Prostate Cancer with Yushen Qian, MD

Stanford University
Add to list
0:00 / 0:00